SynthesisOncotarget2016
Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2021Pooled it
- MicroRNA Dysregulation in HPV-Driven Cervical Cancer: A Review of Oncoprotein-Targeted Signaling Pathways.Life (Basel, Switzerland) · 2026Review
- The diagnostic accuracy of serum and plasma microRNAs in detection of cervical intraepithelial neoplasia and cervical cancer: A systematic review andGynecologic oncology reports · 2024Article
- The diagnostic accuracy of serum microRNAs in detection of cervical cancer: a systematic review protocol.Diagnostic and prognostic research · 2023Article
- Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- MiRNAs: A Powerful Tool in Deciphering Gynecological Malignancies.Frontiers in oncology · 2020Review
- Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers.PeerJ · 2020Article
- Analysis of CASP12 diagnostic and prognostic values in cervical cancer based on TCGA database.Bioscience reports · 2019Article
- MicroRNA-758 inhibits cervical cancer cell proliferation and metastasis by targeting HMGB3 through the WNT/β-catenin signaling pathway.Oncology letters · 2019Article
- Polymorphisms in miRNA genes play roles in the initiation and development of cervical cancer.Journal of Cancer · 2019Article
- MicroRNA-379 Suppresses Cervical Cancer Cell Proliferation and Invasion by Directly Targeting V-crk Avian Sarcoma Virus CT10 Oncogene Homolog-Like (CRKL).Oncology research · 2018Article
- MicroRNA-296 Targets Specificity Protein 1 to Suppress Cell Proliferation and Invasion in Cervical Cancer.Oncology research · 2018Article
- Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer.Oncotarget · 2018Article
- Colorectal neoplasia differentially expressed: a long noncoding RNA with an imperative role in cancer.OncoTargets and therapy · 2018Review
- Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review is written to investigate the outcome of cervical cancer. A comprehensive search of PubMed and EMBASE was performed to identify eligible studies. Nineteen studies from thirteen articles with a total of 1,310 participants were included in this meta-analysis. Overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) as a prognosis for cervical cancer were extracted and calculated, if available. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using STATA (version 12.0), resulting in the pooled HRs 0.70 (95% CI: 0.51-0.97) for OS, 1.02 (95% CI: 0.53-1.98) for DFS, and 0.56 (95% CI: 0.40-0.77) for RFS. The results indicated that cervical cancer patients with decreased microRNA expression were associated with shorter OS and RFS. It suggested that microRNAs might be promising markers for predicting the survival rate of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.